Why the study?
Do CBR3 genotypes correlate with doxorubicin disposition and toxicity in breast cancer patients?
Do CBR3 genotypes correlate with doxorubicin disposition and toxicity in breast cancer patients?
Polymorphisms in the CBR3 gene may explain interindividual and interethnic variability in doxorubicin pharmacokinetics and pharmacodynamics.
No takes yet. Share an insight, caveat, or question.
CBR3 genotyping may inform doxorubicin response variability in breast cancer; hypothesis-generating and requires prospective validation before clinical use.
Fan et al. (2008) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: